Previous 10 | Next 10 |
BridgeBio Pharma (NASDAQ:BBIO) perks up 3% premarket after shedding around 72% during yesterday's intrady session after its late-stage study for acoramidis in transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) did not meet the primary endpoint. Following this news, sever...
With the final days of 2021 counting down, stocks maintained their momentum on Monday, extending recent gains and powering the S&P 500 to yet another closing high. As the calendar barrels towards 2022, several themes that have dominated trading throughout the past year continued to drive ...
Shares of Bridgebio Pharma (NASDAQ: BBIO) , a clinical-stage biotechnology company, are getting crushed after the company reported a disappointing trial failure. Investors mourning the end of the acoramidis program have hammered the stock 70.7% lower as of 11:11 a.m. ET on Monday. ...
Gainers: PyroGenesis Canada (NASDAQ:PYR) +72%. Microbot Medical MBOT +50%. CollPlant Biotechnologies CLGN +32%. Future FinTech FTFT +41%. American Virtual Cloud Technologies (NASDAQ:AVCT) +23%. Spruce Biosciences (NASDAQ:SPRB) +31%. Tarena International TEDU +19%. CNF...
Gainers: Microbot Medical (NASDAQ:MBOT) +51%, CollPlant Biotechnologies (NASDAQ:CLGN) +27%, Lucira Health (NASDAQ:LHDX) +14%, IceCure Medical (NASDAQ:ICCM) +13%, Cue Health (NASDAQ:HLTH) +12%. Losers: BridgeBio Pharma (NASDAQ:BBIO) -71%, Biond...
BridgeBio Pharma (BBIO -71.5%) has reached a 52-week low after announcing that its late-stage study for acoramidis in transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) did not meet the primary endpoint. Commenting on the development, Stifel analysts led by Paul Matteis point out that ...
BridgeBio Pharma (NASDAQ:BBIO) has lost ~67.9% in the pre-market after the company said that its ongoing Phase 3 study for acoramidis in transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) did not meet the primary endpoint at Month 12. Disclosing topline data from the 632-patient A...
- ATTRibute-CM did not meet its primary endpoint at Month 12. Mean observed six-minute walk distance (6MWD) decline for the acoramidis and placebo arms were 9 meters and 7 meters, respectively. Both declines are similar to healthy elderly adults and less than prior untreated ATTR-CM cohor...
This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion in assets under management. After the Q3-2021 13F filings the consensus holdings were updated, 5 stocks were removed and 5 added from the un...
BridgeBio Pharma (BBIO -9.8%) has recorded its sharpest intraday loss since January as the company prepares to report topline results from a late-stage trial for Acoramidis. Also called AG10, Acoramidis is its candidate for rare heart disease, transthyretin amyloid cardiomyopathy (ATTR-CM). D...
News, Short Squeeze, Breakout and More Instantly...
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and...
2024-07-09 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...